APR-548 + Azacitidine
A20-11202
Phase 1 small_molecule terminated
Quick answer
APR-548 + Azacitidine for MDS is a Phase 1 program (small_molecule) at Aprea Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Aprea Therapeutics
- Indication
- MDS
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- terminated